Literature DB >> 28208175

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.

Neeraj Agarwal1, Andrew W Hahn1, David M Gill1, James M Farnham2, Austin I Poole1, Lisa Cannon-Albright1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28208175      PMCID： PMC5824318          DOI： 10.1001/jamaoncol.2017.0147

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Barbara Kuri; Yair Lotan; Claus G Roehrborn; Jiayan Liu; Robert Vessella; Peter S Nelson; Payal Kapur; Xiaofeng Guo; Hamid Mirzaei; Richard J Auchus; Nima Sharifi
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Authors:  Jason W D Hearn; Ghada AbuAli; Chad A Reichard; Chandana A Reddy; Cristina Magi-Galluzzi; Kai-Hsiung Chang; Rachel Carlson; Laureano Rangel; Kevin Reagan; Brian J Davis; R Jeffrey Karnes; Manish Kohli; Donald Tindall; Eric A Klein; Nima Sharifi
Journal:  Lancet Oncol       Date:  2016-08-27       Impact factor: 41.316

Review 3.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.

Authors:  Jacques Simard; Marie-Louise Ricketts; Sébastien Gingras; Penny Soucy; F Alex Feltus; Michael H Melner
Journal:  Endocr Rev       Date:  2005-01-04       Impact factor: 19.871

4.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
  4 in total
  24 in total

1.  AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.

Authors:  Daniel Hettel; Ao Zhang; Mohammad Alyamani; Michael Berk; Nima Sharifi
Journal:  Endocrinology       Date:  2018-08-01       Impact factor: 4.736

2.  Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.

Authors:  Charles Dai; Yoon-Mi Chung; Evan Kovac; Ziqi Zhu; Jianneng Li; Cristina Magi-Galluzzi; Andrew J Stephenson; Eric A Klein; Nima Sharifi
Journal:  Clin Cancer Res       Date:  2017-07-21       Impact factor: 12.531

3.  Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.

Authors:  Charles J Ryan; Sandipan Dutta; William K Kelly; Rob Middleberg; Carly Russell; Michael J Morris; Mary-Ellen Taplin; Susan Halabi
Journal:  Clin Genitourin Cancer       Date:  2019-10-17       Impact factor: 2.872

Review 4.  Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics.

Authors:  Bryan D Naelitz; Nima Sharifi
Journal:  Trends Endocrinol Metab       Date:  2020-06-18       Impact factor: 12.015

Review 5.  HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Authors:  Daniel Hettel; Nima Sharifi
Journal:  Nat Rev Urol       Date:  2017-12-12       Impact factor: 14.432

Review 6.  HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.

Authors:  Navin Sabharwal; Nima Sharifi
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

Review 7.  Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

Authors:  Min Liu; Hongzhe Shi; Jiaqing Yan; Yuan Zhang; Yinglin Ma; Kaidi Le; Zhongdong Li; Nianzeng Xing; Guohui Li
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.

Authors:  Mohammad Alyamani; Hamid Emamekhoo; Sunho Park; Jennifer Taylor; Nima Almassi; Sunil Upadhyay; Allison Tyler; Michael P Berk; Bo Hu; Tae Hyun Hwang; William Douglas Figg; Cody J Peer; Caly Chien; Vadim S Koshkin; Prateek Mendiratta; Petros Grivas; Brian Rini; Jorge Garcia; Richard J Auchus; Nima Sharifi
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

9.  HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.

Authors:  Fei-Fei Han; Lu-Lu Ren; Ling-Ling Xuan; Ya-Li Lv; He Liu; Li-Li Gong; Zhuo-Ling An; Li-Hong Liu
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

10.  HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Jason W D Hearn; Christopher J Sweeney; Nima Almassi; Chad A Reichard; Chandana A Reddy; Hong Li; Brian Hobbs; David F Jarrard; Yu-Hui Chen; Robert Dreicer; Jorge A Garcia; Michael A Carducci; Robert S DiPaola; Nima Sharifi
Journal:  JAMA Oncol       Date:  2020-04-09       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.